Abst1338 #acr21 @RheumNow BE ACTIVE Bimekizumab in 206 PsA: Over half of TNFi-n pts achieved ACR50 resolution of dactylitis (70.2% NRI; 100.0% OC) & enthesitis (60.7% NRI; 80.6% OC) PASI100 at Wks 48/152 63.3/58.7% Low serious infect, mild/moderate candida. 1 microscopic colitis https://t.co/CJXyywZYJd